Literature DB >> 21481194

Post-translational modifications regulate signalling by Ror1.

M Kaucká1, P Krejčí, K Plevová, S Pavlová, J Procházková, P Janovská, J Valnohová, A Kozubík, S Pospíšilová, V Bryja.   

Abstract

AIM: In this study, we analysed the post-translational modification of receptor tyrosine kinase-like orphan receptor (Ror1). Ror1 is highly upregulated in B cells of patients with chronic lymphocytic leukaemia (CLL). Molecularly, Ror1 acts as the Wnt receptor in the non-canonical Wnt pathway.
METHODS: The level of Ror1 glycosylation in HEK293 cells and in primary human CLL cells was analysed by treatment of inhibitors interfering with different steps of glycosylation process and by direct treatment of cell lysates with N-glycosidase. Ror1 ubiquitination was determined by ubiquitination assay. Functional consequences of post-translational modifications were analysed by immunohistochemistry and by analysis of cell surface proteins. Differences in Ror1 glycosylation were confirmed by analysis of 14 samples of B cells from CLL patients.
RESULTS: We demonstrate that Ror1 is extensively modified by N-linked glycosylation. Glycosylation produces several variants of Ror1 with electrophoretic migration of approx. 100, 115 and 130 kDa. Inhibition of glycosylation interferes with cell surface localization of the 130-kDa variant of Ror1 and prevents Ror1-induced formation of filopodia. Moreover, we show that 130-kDa Ror1 is mono-ubiquitinated. Furthermore, individual CLL patients show striking differences in the electrophoretic migration of Ror1, which correspond to the level of glycosylation.
CONCLUSION: Our data show that Ror1 undergoes complex post-translational modifications by glycosylation and mono-ubiquitination. These modifications regulate Ror1 localization and signalling, and are highly variable among individual CLL patients. These may suggest that Ror1 signals only in a subset of CLL patients despite Ror1 levels are ubiquitously high in all CLL patients.
© 2011 The Authors. Acta Physiologica © 2011 Scandinavian Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481194     DOI: 10.1111/j.1748-1716.2011.02306.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  15 in total

1.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Authors:  Ashwini Balakrishnan; Tracy Goodpaster; Julie Randolph-Habecker; Benjamin G Hoffstrom; Florencia G Jalikis; Lisa K Koch; Carolina Berger; Paula L Kosasih; Anusha Rajan; Daniel Sommermeyer; Peggy L Porter; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

2.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Authors:  Jenny Potratz; Amelie Tillmanns; Philipp Berning; Eberhard Korsching; Christiane Schaefer; Birgit Lechtape; Carolin Schleithoff; Rebekka Unland; Karl-Ludwig Schäfer; Carsten Müller-Tidow; Heribert Jürgens; Uta Dirksen
Journal:  Mol Oncol       Date:  2015-12-20       Impact factor: 6.603

3.  Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.

Authors:  Pavlina Janovska; Lucie Poppova; Karla Plevova; Hana Plesingerova; Martin Behal; Marketa Kaucka; Petra Ovesna; Michaela Hlozkova; Marek Borsky; Olga Stehlikova; Yvona Brychtova; Michael Doubek; Michaela Machalova; Sivasubramanian Baskar; Alois Kozubik; Sarka Pospisilova; Sarka Pavlova; Vitezslav Bryja
Journal:  Clin Cancer Res       Date:  2015-08-03       Impact factor: 12.531

4.  ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.

Authors:  Guilly Rebagay; Su Yan; Cheng Liu; Nai-Kong Cheung
Journal:  Front Oncol       Date:  2012-04-18       Impact factor: 6.244

5.  The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

Authors:  Mohammad Hojjat-Farsangi; Abdul Salam Khan; Amir Hossein Daneshmanesh; Ali Moshfegh; Asa Sandin; Ladan Mansouri; Marzia Palma; Jeanette Lundin; Anders Österborg; Håkan Mellstedt
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

Review 6.  ROR1, an embryonic protein with an emerging role in cancer biology.

Authors:  Nicholas Borcherding; David Kusner; Guang-Hui Liu; Weizhou Zhang
Journal:  Protein Cell       Date:  2014-04-22       Impact factor: 14.870

7.  Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Authors:  Hana Plešingerová; Pavlína Janovská; Archana Mishra; Lucie Smyčková; Lucie Poppová; Antonín Libra; Karla Plevová; Petra Ovesná; Lenka Radová; Michael Doubek; Šárka Pavlová; Šárka Pospíšilová; Vítězslav Bryja
Journal:  Haematologica       Date:  2017-11-09       Impact factor: 9.941

8.  A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Authors:  Amir Hossein Daneshmanesh; Mohammad Hojjat-Farsangi; Amineh Ghaderi; Ali Moshfegh; Lotta Hansson; Johan Schultz; Jan Vågberg; Styrbjörn Byström; Elisabeth Olsson; Thomas Olin; Anders Österborg; Håkan Mellstedt
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

9.  Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Authors:  Mohammad Hojjat-Farsangi; Fatemeh Ghaemimanesh; Amir Hossein Daneshmanesh; Ali-Ahmad Bayat; Jafar Mahmoudian; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Hakan Mellstedt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

10.  Multi-Compartment and Multi-Host Vector Suite for Recombinant Protein Expression and Purification.

Authors:  Claudia Ortega; Daniel Prieto; Cecilia Abreu; Pablo Oppezzo; Agustín Correa
Journal:  Front Microbiol       Date:  2018-06-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.